Glow-in-the-Dark dye could help surgeons spot lung cancer
NCT ID NCT06713564
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 32 times
Summary
This early-stage trial tested a new fluorescent dye called LS301-IT in 24 people having lung cancer surgery. The dye is designed to attach to cancer cells and glow under a special light, helping surgeons see tumors more clearly. The main goals were to check safety and see how well the dye works at different doses and times before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LS301-IT (a fluorescent dye that binds to cancer cells and glows under near-infrared light)
What this could lead to
If successful, this could give surgeons a real-time tool to see lung cancer during surgery, potentially helping them remove all cancerous tissue more precisely.
What could go wrong
This is an early phase 1 trial with only 24 people, focused mainly on safety. The dye may not work well in all patients, and there is a risk of allergic reactions or other side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.